#celltrion — Public Fediverse posts

Celltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments
#YonhapInfomax #Celltrion #Zymfentra #Biosimilars #CMS #MedicareAdvantage #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114387

Celltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments
#YonhapInfomax #Celltrion #Zymfentra #Biosimilars #CMS #MedicareAdvantage #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114387

Celltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments
#YonhapInfomax #Celltrion #Zymfentra #Biosimilars #CMS #MedicareAdvantage #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114387

Celltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments
#YonhapInfomax #Celltrion #Zymfentra #Biosimilars #CMS #MedicareAdvantage #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114387

Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173

Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173

Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173

Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173

Celltrion Co. has implemented measures to ensure its US business remains unaffected by any tariff policy changes, leveraging local production and inventory to maintain stable operations.
#YonhapInfomax #Celltrion #USTariffs #BranchburgPlant #EliLilly #BusinessOperations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106952

Celltrion Co. has implemented measures to ensure its US business remains unaffected by any tariff policy changes, leveraging local production and inventory to maintain stable operations.
#YonhapInfomax #Celltrion #USTariffs #BranchburgPlant #EliLilly #BusinessOperations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106952

Celltrion Co. has implemented measures to ensure its US business remains unaffected by any tariff policy changes, leveraging local production and inventory to maintain stable operations.
#YonhapInfomax #Celltrion #USTariffs #BranchburgPlant #EliLilly #BusinessOperations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106952

Celltrion Co. has implemented measures to ensure its US business remains unaffected by any tariff policy changes, leveraging local production and inventory to maintain stable operations.
#YonhapInfomax #Celltrion #USTariffs #BranchburgPlant #EliLilly #BusinessOperations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106952

LG Electronics and Celltrion are the only South Korean firms to rank in S&P Global's ESG Top 1% for 2026, highlighting LG's sustained global leadership in sustainability for three consecutive years.
#YonhapInfomax #LGElectronics #SPGlobal #ESG #Celltrion #SustainabilityYearbook2026 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106019

LG Electronics and Celltrion are the only South Korean firms to rank in S&P Global's ESG Top 1% for 2026, highlighting LG's sustained global leadership in sustainability for three consecutive years.
#YonhapInfomax #LGElectronics #SPGlobal #ESG #Celltrion #SustainabilityYearbook2026 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106019

LG Electronics and Celltrion are the only South Korean firms to rank in S&P Global's ESG Top 1% for 2026, highlighting LG's sustained global leadership in sustainability for three consecutive years.
#YonhapInfomax #LGElectronics #SPGlobal #ESG #Celltrion #SustainabilityYearbook2026 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106019

LG Electronics and Celltrion are the only South Korean firms to rank in S&P Global's ESG Top 1% for 2026, highlighting LG's sustained global leadership in sustainability for three consecutive years.
#YonhapInfomax #LGElectronics #SPGlobal #ESG #Celltrion #SustainabilityYearbook2026 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106019

Celltrion Co. posts record 2025 results, surpassing 4 trillion won in revenue and 1 trillion won in operating profit, driven by high-margin new biosimilars and robust global sales.
#YonhapInfomax #Celltrion #OperatingProfit #Biosimilars #GlobalSales #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103936

Celltrion Co. posts record 2025 results, surpassing 4 trillion won in revenue and 1 trillion won in operating profit, driven by high-margin new biosimilars and robust global sales.
#YonhapInfomax #Celltrion #OperatingProfit #Biosimilars #GlobalSales #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103936

Celltrion Co. posts record 2025 results, surpassing 4 trillion won in revenue and 1 trillion won in operating profit, driven by high-margin new biosimilars and robust global sales.
#YonhapInfomax #Celltrion #OperatingProfit #Biosimilars #GlobalSales #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103936

Celltrion is accelerating the global rollout of its ophthalmic drug Eyedenzelt, securing key markets in the US, Canada, and Europe through strategic patent settlements and differentiated market entry strategies.
#YonhapInfomax #Celltrion #Eyedenzelt #PatentSettlement #GlobalMarket #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99424

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

Celltrion Group Chairman Seo Jung-jin announced a three-year AI-driven innovation plan through 2028, aiming for a quantum leap in biosimilars, digital healthcare, and global expansion.
#YonhapInfomax #Celltrion #SeoJungJin #ArtificialIntelligence #Biosimilars #DigitalHealthcare #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98140

Celltrion Group Chairman Seo Jung-jin announced a three-year AI-driven innovation plan through 2028, aiming for a quantum leap in biosimilars, digital healthcare, and global expansion.
#YonhapInfomax #Celltrion #SeoJungJin #ArtificialIntelligence #Biosimilars #DigitalHealthcare #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98140

Celltrion Group Chairman Seo Jung-jin announced a three-year AI-driven innovation plan through 2028, aiming for a quantum leap in biosimilars, digital healthcare, and global expansion.
#YonhapInfomax #Celltrion #SeoJungJin #ArtificialIntelligence #Biosimilars #DigitalHealthcare #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98140

Celltrion Group Chairman Seo Jung-jin announced a three-year AI-driven innovation plan through 2028, aiming for a quantum leap in biosimilars, digital healthcare, and global expansion.
#YonhapInfomax #Celltrion #SeoJungJin #ArtificialIntelligence #Biosimilars #DigitalHealthcare #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98140

South Korean brokerages have raised Celltrion's target price to 250,000 won, citing strong Q4 earnings, expanding high-margin product sales, and growth prospects from its U.S. CMO business.
#YonhapInfomax
#Celltrion #TargetPrice #Q4Earnings #HighMarginProducts #CMOBusiness
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98007

South Korean brokerages have raised Celltrion's target price to 250,000 won, citing strong Q4 earnings, expanding high-margin product sales, and growth prospects from its U.S. CMO business.
#YonhapInfomax
#Celltrion #TargetPrice #Q4Earnings #HighMarginProducts #CMOBusiness
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98007

South Korean brokerages have raised Celltrion's target price to 250,000 won, citing strong Q4 earnings, expanding high-margin product sales, and growth prospects from its U.S. CMO business.
#YonhapInfomax
#Celltrion #TargetPrice #Q4Earnings #HighMarginProducts #CMOBusiness
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98007

South Korean brokerages have raised Celltrion's target price to 250,000 won, citing strong Q4 earnings, expanding high-margin product sales, and growth prospects from its U.S. CMO business.
#YonhapInfomax
#Celltrion #TargetPrice #Q4Earnings #HighMarginProducts #CMOBusiness
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98007

Celltrion has completed its acquisition of a New Jersey biopharmaceutical plant from Eli Lilly, aiming to reduce US tariff risks and expand its US market presence, with plans for major capacity investment and a $473 million supply contract.
#YonhapInfomax #Celltrion #EliLilly #TariffRisks #Biopharmaceuticals #NewJerseyFacility #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97993

Celltrion has completed its acquisition of a New Jersey biopharmaceutical plant from Eli Lilly, aiming to reduce US tariff risks and expand its US market presence, with plans for major capacity investment and a $473 million supply contract.
#YonhapInfomax #Celltrion #EliLilly #TariffRisks #Biopharmaceuticals #NewJerseyFacility #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97993

Celltrion has completed its acquisition of a New Jersey biopharmaceutical plant from Eli Lilly, aiming to reduce US tariff risks and expand its US market presence, with plans for major capacity investment and a $473 million supply contract.
#YonhapInfomax #Celltrion #EliLilly #TariffRisks #Biopharmaceuticals #NewJerseyFacility #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97993

Celltrion has completed its acquisition of a New Jersey biopharmaceutical plant from Eli Lilly, aiming to reduce US tariff risks and expand its US market presence, with plans for major capacity investment and a $473 million supply contract.
#YonhapInfomax #Celltrion #EliLilly #TariffRisks #Biopharmaceuticals #NewJerseyFacility #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97993

Celltrion announced it cannot proceed with an extraordinary general meeting requested by minority shareholders, citing insufficient legal documentation, but is considering voluntary agenda items for the next regular meeting.
#YonhapInfomax #Celltrion #MinorityShareholders #ExtraordinaryGeneralMeeting #LegalRequirements #TreasuryShareCancellation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=96214

Celltrion announced it cannot proceed with an extraordinary general meeting requested by minority shareholders, citing insufficient legal documentation, but is considering voluntary agenda items for the next regular meeting.
#YonhapInfomax #Celltrion #MinorityShareholders #ExtraordinaryGeneralMeeting #LegalRequirements #TreasuryShareCancellation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=96214

Celltrion announced it cannot proceed with an extraordinary general meeting requested by minority shareholders, citing insufficient legal documentation, but is considering voluntary agenda items for the next regular meeting.
#YonhapInfomax #Celltrion #MinorityShareholders #ExtraordinaryGeneralMeeting #LegalRequirements #TreasuryShareCancellation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=96214

Celltrion announced it cannot proceed with an extraordinary general meeting requested by minority shareholders, citing insufficient legal documentation, but is considering voluntary agenda items for the next regular meeting.
#YonhapInfomax #Celltrion #MinorityShareholders #ExtraordinaryGeneralMeeting #LegalRequirements #TreasuryShareCancellation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=96214

Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705

Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705

Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705

Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705

Celltrion Holdings is ramping up share buybacks, issuing convertible bonds worth 2.5 trillion won ($1.9 billion) to support Celltrion's stock price, with total purchases this year reaching 8.741 trillion won ($6.6 billion), as the group seeks to enhance shareholder value amid sluggish share performance.
#YonhapInfomax #CelltrionHoldings #ConvertibleBonds #ShareBuyback #Celltrion #OperatingProfit #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=94320

Celltrion Holdings is ramping up share buybacks, issuing convertible bonds worth 2.5 trillion won ($1.9 billion) to support Celltrion's stock price, with total purchases this year reaching 8.741 trillion won ($6.6 billion), as the group seeks to enhance shareholder value amid sluggish share performance.
#YonhapInfomax #CelltrionHoldings #ConvertibleBonds #ShareBuyback #Celltrion #OperatingProfit #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=94320

Celltrion Holdings is ramping up share buybacks, issuing convertible bonds worth 2.5 trillion won ($1.9 billion) to support Celltrion's stock price, with total purchases this year reaching 8.741 trillion won ($6.6 billion), as the group seeks to enhance shareholder value amid sluggish share performance.
#YonhapInfomax #CelltrionHoldings #ConvertibleBonds #ShareBuyback #Celltrion #OperatingProfit #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=94320

Celltrion Holdings is ramping up share buybacks, issuing convertible bonds worth 2.5 trillion won ($1.9 billion) to support Celltrion's stock price, with total purchases this year reaching 8.741 trillion won ($6.6 billion), as the group seeks to enhance shareholder value amid sluggish share performance.
#YonhapInfomax #CelltrionHoldings #ConvertibleBonds #ShareBuyback #Celltrion #OperatingProfit #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=94320

Celltrion Holdings Co. will issue 250 billion won ($190 million) in convertible bonds, likely to fund further purchases of Celltrion shares, following a similar 500 billion won CB issuance in August.
#YonhapInfomax #CelltrionHoldings #ConvertibleBonds #Celltrion #ShareAcquisition #250BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=94219

Celltrion Holdings Co. will issue 250 billion won ($190 million) in convertible bonds, likely to fund further purchases of Celltrion shares, following a similar 500 billion won CB issuance in August.
#YonhapInfomax #CelltrionHoldings #ConvertibleBonds #Celltrion #ShareAcquisition #250BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=94219